Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial
Abstract
Abstract Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients ≤60 years but 56% (95% CI 17-82%) for patients >60 years, p = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.
Article Details
Authors (29)
Kamil A. Rechache
Natalia S. Nunes
Jennifer Sponaugle
Elisabetta Xue
Amy Chai
Rebecca Combs
Jessenia Campos
Xingmin Feng
Francis A. Flomerfelt
Kalpana Upadhyaya
William Telford
Brian Dawson
Thomas E. Hughes
Syed Muhammad Salman Shah
Alicia Peluso
Christi McKeown
Anita Stokes
Scott Napier
Ruby Sabina
Jennifer Wilder
Kristen Cole
Judy Baruffaldi
Jennifer Cuellar-Rodriguez
Juan Gea-Banacloche
Mary M. Czech
Mustafa A. Hyder
Christopher G. Kanakry
Dimana Dimitrova
Jennifer A. Kanakry